Helpful resources to keep you, your family and kids safe during RSV season.
Earlier this year, the FDA approved a therapeutic to prevent severe cases of respiratory syncytial virus in children. What do you need to know about the new drug and RSV? We asked a pediatric infectious disease expert.
It’s the time of the year when holiday festivities excite us, and winter illnesses like RSV infection may sideline us.
Respiratory syncytial virus (RSV) season typically begins in the fall and peaks during winter. The virus, which features cold-like symptoms, affects people of all ages, though children are particularly prone to it. Babies — especially preterm infants, those with health issues and any infant younger than 6 months old — are at risk for hospitalization with RSV. And even though there is no specific treatment for the virus, earlier this year, the Food and Drug Administration (FDA) approved a new therapeutic in the form of a shot to prevent severe cases of RSV and hospitalization in babies and toddlers. Supply is limited but talk to your pediatrician to see if your infant is eligible for the therapeutic.
In the meantime, we spoke with Rachel Orscheln, MD, a Washington University physician at St. Louis Children’s Hospital who specializes in pediatric infectious disease, regarding everything you need to know about RSV, including when to seek medical care and what the new therapeutic is designed to do.
Parents are encouraged to ask their pediatrician if their children are eligible for the new RSV therapeutic. Need help finding a pediatrician? Use our online search feature to find a doctor who is accepting new patients near you.